Physician profile
Erika Korbaj
NPI 1518602028
$3,520.83
in general payments reported to CMS, 2019-2025
18 companies · $701 in 2025
The $701 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $1,752 · 2024: $877 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.76 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.79 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $708.63 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $689.47 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $237.24 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $148.22 | 2022 | |
| Intuitive Surgical, INC. | $117.62 | 2023 | Da Vinci Surgical System |
| Vanda Pharmaceuticals INC. | $106.99 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $84.02 | 2024-2025 | Trintellix |
| Lilly USA, LLC | $62.42 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $58.26 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.53 | 2024 | Caplyta |
| Neurocrine Biosciences, INC. | $42.91 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $40.27 | 2025 | Rexulti |
| Dexcom, INC. | $39.82 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $33.99 | 2023-2024 | Rybelsus, Ozempic |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.52 | 2022 | |
| Alkermes, INC. | $18.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.80 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Korbaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.